Skip to content

A series of studies on the combined treatment of liver cancer using targeted and immunotherapy in the real world and transcatheter arterial chemoembolization

A series of studies on the combined treatment of liver cancer using targeted and immunotherapy in the real world and transcatheter arterial chemoembolization

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118057
Enrollment
Unknown
Registered
2026-02-02
Start date
2024-03-01
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Sponsors

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.The age is not less than 18 years old, and no more than 80 years old. 2.Patients can be diagnosed as HCC according to clinical or pathological evidences. 3.The treatments of local lesions include c-TACE and d-TACE, allowing pre-surgery or postoperative use of targeted therapy and immunotherapy.

Exclusion criteria

Exclusion criteria: 1.Patients underwent surgeries within one month before interventions, including preventive embolism. 2.There are severe infections or organ failure. 3.There are severe liver dysfunction (Child -Pugh C). 4.ECOG score is 2 points or more. 5.Loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Objective response rate;

Secondary

MeasureTime frame
Disease control rate;Overall survival period;Progression-free survival period;

Countries

China

Contacts

Public ContactZhou Haifeng

The First Affiliated Hospital of Nanjing Medical University

hyphone@139.com+86 15298372811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026